Sintilimab treatment for chronic active Epstein–Barr virus infection and Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children

Abstract Background Chronic active Epstein–Barr virus infection (CAEBV) and Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) are rare but life-threatening progressive diseases triggered by EBV infection. Glucocorticoid/immunosuppressants treatment is temporarily effective;...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ruyue Chen, Qiang Lin, Yun Zhu, Yunyan Shen, Qinying Xu, Hanyun Tang, Ningxun Cui, Lu Jiang, Xiaomei Dai, Weiqing Chen, Xiaozhong Li
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2023-09-01
Edice:	Orphanet Journal of Rare Diseases
Témata:	Epstein–Barr virus (EBV) Chronic active Epstein–Barr virus infection (CAEBV) Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) Programmed cell death 1 (PD-1) Sintilimab
On-line přístup:	https://doi.org/10.1186/s13023-023-02861-9
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!